Proactive Investors - Run By Investors For Investors

Breakfast News - AIM Breakfast : Walls & Futures, REIT Plc, Be Heard Group, EKF Diagnostics, Keywords Studios PLC, LiDCO Group plc, Ncondezi Energy, Netscientific PLC, Provexis, Warpaint London plc, XLMedia

Breakfast News - AIM Breakfast : Walls & Futures, REIT Plc, Be Heard Group, EKF Diagnostics, Keywords Studios PLC, LiDCO Group plc, Ncondezi Energy, Netscientific PLC, Provexis, Warpaint London plc, XLMedia

What’s cooking in the IPO kitchen?

AIM I3 Energy – Schedule 1. Independent oil and gas company with assets and operations in the UK. Offer TBC, 26 May admission.

Opera Investments – Reverse Takeover of Kibo Mining’s subsidiary Kibo Gold. Raising £1.5m. Expected mkt Cap £6.5m. 23 May.

Eve Sleep—  Schedule 1 from the e-commerce focused, direct to consumer European sleep brand. Offer details TBC. Expected Mid May

Velocity Composites—Schedule 1. Manufactures advanced carbon fibre and ancillary material kits (predominantly carbon fibre) for use in the production of aircraft. Mid May admission expected. Offer details TBC.

Verditek— Schedule 1 update. On Admission, the Company's subsidiaries will be involved in advanced solar photovoltaic, filtration and absorption technologies specialising in providing environmental services. Issue price 10p. Admission in May.

Main Market Premium Listing

Alfa Financial Software – Intention to float. Mission-critical software platform purpose-built for asset finance enterprises. Vendor sale of 25% plus. FYDec16 rev £73.3m (CAGR of 24% from 2012). Adjusted EBIT £32.8m,

Kuwait Energy - $150m raise plus vendor offer. Admission due June. 2p reserves 810.0mmboe

Main Market Standard Listing

ADES International - Provider of offshore and onshore oil and gas drilling and production services in the Middle East and Africa, seeking raise up to $170m plus vendor sale under a Standard Listing of the Main MArket. Admission due May 2017.

Global Ports Holding - Intention to float on Standar List of the Main Market. International cruise ports operator. Seeking $200m + raise including $75m primary offer. Expected price range 735p to 875p. Mkt cap up to £539m.

Main Market Specialist Funds

Tufton Oceanic Assets - Offer extended to 9 May on specialist funds segment of Main Market to enable investors to complete further due diligence.

PRS REIT - Private rental sector REIT raising up to £250m. Admission due 31 May 

 

 

Breakfast buffet

Provexis (LON:PXS) 0.62p £10.42m

The Company that develops licenses and sell the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient  has provided an update on trading. The Company expects to report on a strong year of progress. Provexis’ Alliance partner, DSM Nutritional Products, has continued to develop the market actively for Fruitflow® in all global markets. More than 50 regional consumer healthcare brands have now been launched by direct customers of DSM. Revenues for year ending 31 Mar 2017 were £228k, up 148% on the previous year, of which £153k were from the profit sharing Alliance for Fruitflow®.  The Company expects to report an underlying operating loss of £382k (2016:£385k). Provexis also announced a placing of £350k at 0.5p (16.7% discount to closing price on 9 May2017). Proceeds will be used as additional working capital, to support revenue growth and to strengthen the Group’s balance sheet.

Walls & Futures REIT (NEX:WAFR) 82.5p £2.7m

The Company has completed on its first residential investment in the Supported Housing Sector announced earlier this week. The Company has acquired the freehold of a detached grade two listed building, in the Cotswold market town of Stroud, for £475,000. The Company has also committed to contribute towards the improvement and redevelopment of the property that is due to be carried out over the next 3 to 4 months. Once those works are completed the property will provide a high quality home and specialist support to six adults with physical & learning disabilities and/or mental health needs.  The property is being let on a 25-year full repairing and insuring lease, with rents adjusted annually in line with inflation (CPI), to one of the UK's leading care providers.

Ncondezi Energy (LON:NCCL) 2.15p £5.56m

In accordance with its terms, the Shareholder Loan has become repayable and has increased from 1.5x to 2.0x the loan amount outstanding. A total of US$2,192,546 has been drawn down under the Shareholder Loan and the repayment amount is now US$4,385,092. The Company is in advanced negotiations with loan holders regarding  extension of repayment. Whilst discussions are  advanced, there can be no certainty that an extension will be agreed.  Discussions with Shanghai Electric Power  are continuing with respect to the US$3m Development Agreement which would fund ongoing project development work on the power project and finalise SEP's investment through the Joint Development Agreement. The Company expects to update shareholders on this process this Month. Working on further funding.

Be Heard Group (LON:BHRD) 3.7p £29.78m

AGM Statement from  the digital marketing services group. 2017 has started well and Be Heard is trading in line with the Board's expectations. MMT in particular is growing strongly as Group cross referrals start to impact. New business wins this year include Cath Kidston, BDO and Brakes at agenda21, PPG, Sense, Save the Children and Gowling WLG at MMT Digital and Clyde & Co, the Society of Petroleum Engineers and ACCA at Kameleon. We have also made further progress broadening existing client relationships with Vodafone, Essilor, Northumbria Water, Wiltshire Farm Foods and BDO served by two or more partners within the Group. FYDec17E rev £19.5m and £2.3m PBT.

NetScientific (LON:NSCI) 53p £27.07m

The Company’s portfolio company, ProAxsis, has secured a second licensing agreement with Queen University of Belfast for exclusive IP rights for it ProteaseTag technology. ProAxsis develops point of care diagnostics for the capture, detection and measurement of active protease biomarkers of respiratory disease. This agreement, which strengthens the Company's IP portfolio, puts ProAxsis in a great position to launch further immunoassays and point of care tests and build the value of this technology.

XLMedia (LON:XLM) 121.7p £243.92m

The provider of digital performance marketing announced that it has commenced activities in Romania. The Company has been granted a Class 2 License form the Romanian National Gambling Office allowing it to operate as an online gambling affiliate. Following the license being granted, the Group acquired a portfolio of websites offering online betting and gambling content for a total consideration of c.£1m.

LiDCO Group plc (LON:LID) 7.25p £17.70m

The hemodynamic monitoring Company provided an AGM statement. Recruitment is proceeding to plan, having recruited 8 out of the intended 13 additional sales & marketing FTEs planned for this year. The additional resources will be deployed in the USA, UK, Europe and Middle East. The Company’s new monitor, LiDCOunity v2, has now received CE mark and preparation is now under way for commercial launch in Europe. FDA510k review is also under way for launch in the US. The Company is making additional investment in their commercial operations, which they hope will allow for significant sales growth. Revenue to date remains in line with expectations.

Keywords Studio (LON:KWS) 795p £440.3m

The Company announces that is has acquired XLOC Inc. for a total consideration of  $o.9m. XLOC has developed a web-based integrated globalisation content management system for videogames, supported by consulting and customisation services. Its proprietary software can be integrated with any games development platform.  The acquisition is in line with the Company’s strategy to extend its services, with the objective of providing end to end services to its global client base covering all aspects of game production and live operations support. The Company is paying $700k in cash with 19,134 new ordinary shares in Keywords.

Warpaint London (LON:W7L) 211p £136.74m

The specialist supplier of colour cosmetics and the owner of the W7 brand announced its final results. Profit before tax was £4.4m (proforma £5.0m) on a turnover of £22.5m (proforma £27.0m) with basic EPS of 5.07p (proforma 5.84p). Net cash at 31 Dec 2016 of £3.5m underpins the balance sheet and leaves the Group in a strong position going forward. The Board also recommended a final dividend of 1.5p per share. Overseas business will continue to be a major driver as the Company aim to gain a larger share of the global colour cosmetics market. With a flexible supplier base and a tight control of working capital the business remains inherently cash generative.

EKF Diagnostics (LON:EKF) 21.49p £99.20m

The point-of-care business updated shareholders on its current trading and possible demerger. The Company announced that trading in the first quarter was ahead of budget and attributable to organic growth. However, the Board provide no guarantee that this will continue for the year given the relatively short lead time on new orders. The Directors are also evaluating the plans the split the Company into two separate legal entities: Point of Care and Lab Diagnostics. The Directors believe that splitting the Company will represent a better route for shareholders and where they are likely to achieve fair reflection of the value of each business. The Company also continues to evaluate the possibility of a share buyback offer of up to 15% of the Company’s current issued share capital.

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use